Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential - GBI Research Reports

Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential

Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential - GBI Research Reports
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
Published Dec 22, 2010
77 pages — Published Dec 22, 2010
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest report, 'Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential' that provides key data, information and analysis of the major trends and issues in Nanotechnology in Drug Delivery market. The report provides a comprehensive insight into the role of Nanotechnology in Drug Delivery. The report also provides a detailed analysis of market characterization of nanotechnology in drug delivery market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the technological trends over the years in use of nanotechnology in drug delivery.

Scope

The scope of the report includes:
- Detailed overview of Nanotechnology in Drug Delivery in pharmaceutical industry along with their use, efficiency and limitation.
- Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography.
- Key market drivers and restraints shaping the Nanotechnology in Drug Delivery market.
- Competitive landscape analysis with competitive profiling of leading companies.
- Analysis of partnership deals from 2006 to 2010
- Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Develop better strategies for Nanotechnology in Drug Delivery market by understanding the market dynamics.
- Develop market-entry and market expansion strategies by identifying the key development area
- Understand the factors shaping the Nanotechnology in Drug Delivery
- For understanding the technological trends in the market.
- Identify the key players best positioned to take the advantage of the opportunities in the global market.
- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

  
Source:
Document ID
GBIHC043MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents34
1.1 List of Tables61
1.2 List of Figures61
2 Nanotechnology in Drug Delivery Introduction 72
2.1 Introduction 71
2.2 GBI Research Report Guidance81
3 Application of Nanotechnology in Drug Delivery 94
Current Applications of Nano-enabled Drug Delivery91
3.1.1 Nano-engineered drugs 91
3.1.1.1 Nano Crystals91
3.1.1.2 Nano Suspensions91
3.1.2 Nano-carriers101
3.1.2.1 Carbon and Ceramic Nanostructures101
3.1.2.2 Dendrimers101
3.1.2.3 Liposomes101
3.1.2.4 Micelles and Polymeric Nanoparticles101
3.2 Future Applications of Nano-enabled Drug Delivery111
Gene and Vaccine Delivery111
3.2.2 Controlled-Release Devices121
Increased Biocompatibility121
3.2.4 Improved Drug Bioavailability and Solubility121
3.2.5 Applied Diagnosis, Etiology, Prognosis and Therapy (ADEPT)121
3.2.6 Tissue Specific Delivery121
4 Nanotechnology in Drug Delivery Case Studies133
4.1 Abraxis Bioscience, Inc. Paclitaxel-Albumin Nanoparticles (Abraxane)131
4.2 Nanospectra Biosciences AuroShell Particles131
4.3 Calando Pharmaceuticals, Inc. RONDEL Technology131
4.4 Starpharma Holdings, Ltd. Dendrimer-Based VivaGel141
4.5 Mersana Therapeutics: Fleximer Camptothecin Conjugate 141
Elan Corporation NanoCrystal Technology142
5 Nanotechnology in Drug Delivery Market Characterization1624
5.1 Introduction161
5.2 Nano-enabled Drug Delivery Market Drivers161
5.2.1 Clinical Benefits of Nano-enabled Drug delivery161
Value Addition to Existing Pharmaceutical Products through Reformulation161
5.2.3 Strong Pipeline Portfolio161
Nano-Enabled Drug Delivery Market Barriers 171
5.3.1 Poor R&D Facilities and Time Gap between Research and Commercialization171
5.3.2 Lack of Consistent Policy on Technology Transfer and Lack of Capacity to Produce Products171
5.3.3 Regulatory Hindrance 171
5.4 Opportunity and Unmet Need Drug Delivery181
5.4.1 Opportunities181
5.4.1.1 Opportunities for New Drug Delivery Company181
5.4.1.2 Higher Growth Potential for Nano-Enabled Drugs181
5.4.1.3 Licensing Opportunity181
Unmet Need 181
5.4.2.1 Toxicity of Nanomaterials 181
5.4.2.2 Need to Understand Biological Behavior and Distribution Patterns of Nanomaterials191
5.5 Selected Nano-Enabled Therapeutics Approved by the FDA201
5.5.1 Doxil (Caelyx)201
5.5.1.1 Overview201
5.5.1.2 Mechanism of Action201
5.5.1.3 Clinical Trial Details201
5.5.2 Abraxane211
5.5.2.1 Overview211
5.5.2.2 Mechanism of Action211
5.5.2.3 Clinical Trial Details211
5.5.3 AmBisome221
5.5.3.1 Overview221
5.5.3.2 Mechanism of Action221
5.5.3.3 Clinical Trial Details221
5.5.4 Diprivan231
5.5.4.1 Overview231
5.5.4.2 Mechanism of Action231
5.5.4.3 Clinical Trial Details231
5.5.5 Triglide241
5.5.5.1 Overview241
5.5.5.2 Mechanism of Action241
5.5.5.3 Clinical Trial Details251
5.5.6 Myocet251
5.5.6.1 Overview251
5.5.6.2 Mechanism of Action251
5.5.6.3 Clinical Trial Details251
5.5.7 DepoCyt261
5.5.7.1 Overview261
5.5.7.2 Mechanism of Action261
5.5.7.3 Clinical Trial Details261
5.5.8 DaunoXome271
5.5.8.1 Overview271
5.5.8.2 Mechanism of Action271
5.5.8.3 Clinical Trial Details271
Estrasorb271
5.5.9.1 Overview271
5.5.9.2 Mechanism of Action281
5.5.9.3 Clinical Trial Details281
5.5.10 Macugen281
5.5.10.1 Overview281
5.5.10.2 Mechanism of Action281
5.5.10.3 Clinical Trial Details281
5.5.11 Abelcet291
5.5.11.1 Overview291
5.5.11.2 Mechanism of Action291
5.5.12 Adagen301
5.5.12.1 Overview301
5.5.12.2 Mechanism of Action301
Pegasys301
5.5.13.1 Overview301
5.5.13.2 Mechanism of Action301
5.5.13.3 Clinical Trial Details302
5.5.14 Somavert321
5.5.14.1 Overview321
5.5.14.2 Mechanism of Action321
5.5.14.3 Clinical Trial Details321
Neulasta331
5.5.15.1 Overview331
5.5.15.2 Mechanism of Action331
5.5.15.3 Clinical Trial Details331
5.5.16 Copaxone341
5.5.16.1 Overview341
5.5.16.2 Mechanism of Action341
5.5.16.3 Clinical Trial Details341
5.5.17 Amphotec351
5.5.17.1 Overview351
5.5.17.2 Mechanism of Action351
5.5.17.3 Clinical Trial Details351
5.5.18 PegIntron351
5.5.18.1 Overview351
5.5.18.2 Mechanism of Action361
5.5.18.3 Clinical Trial Details361
5.5.19 Oncaspar371
5.5.19.1 Overview371
5.5.19.2 Mechanism of Action371
5.5.19.3 Clinical Trial Details371
Epaxal381
5.5.20.1 Overview381
5.5.20.2 Mechanism of Action381
5.5.20.3 Clinical Trial Details381
Elestrin381
5.5.21.1 Overview381
5.5.21.2 Mechanism of Action381
5.5.21.3 Clinical trial details391
6 Nanotechnology in Drug Delivery Trend Analysis402
6.1 Increasing Government Funding for Nanotechnology R&D 401
6.2 Increasing Seed and Early-Stage Venture Capital401
6.3 Creation of a New Registration Category for Nanotechnology Products within the USPTO401
6.4 Genericization and Emerging Business Models Driving a Need for Novel Drug Delivery Methods 411
7 Nanotechnology in Drug Delivery Regulatory Landscape427
Introduction 422
7.2 Europe441
7.2.1 REACH Regulation 442
7.2.2 European Medicines Agency 461
The US461
7.3.1 Environment Protection Agency461
7.3.2 Food and Drug Administration471
7.3.3 National Institute of Occupational Safety and Health471
7.4 Japan481
8 Nanotechnology in Drug Delivery Pipeline Analysis 496
Overview 491
8.1.1 Pipeline Analysis by Phase501
8.1.1.1 Nano-Enabled Drug Delivery Systems Regulatory Filing Stage501
8.1.1.2 Nano-enabled Drug Delivery Systems Phase III Clinical Pipeline511
8.1.1.3 Nano-enabled Drug Delivery Systems Phase II Clinical Pipeline511
8.1.1.4 Nano-enabled Drug Delivery Systems Phase I Clinical Pipeline521
8.1.1.5 Nano-enabled Drug Delivery Systems Preclinical pipeline531
8.1.1.6 Nano-enabled Drug Delivery Systems Discovery Pipeline541
9 Nanotechnology in Drug Delivery Strategic Consolidations5510
Overview551
9.2 Mergers and Acquisitions551
9.2.1 Mergers and Acquisitions by Geography551
9.2.2 Mergers and Acquisitions by Deal value 561
9.2.3 Mergers and Acquisition Analysis by Deal Type 571
9.3 Summary of Major M&A Deals581
9.3.1 AstraZeneca Acquires MedImmune581
9.3.2 Pfizer Completes Acquisition of Wyeth581
9.3.3 Celgene Announces To Acquire Abraxis BioScience581
9.3.4 Amgen Acquires Abgenix591
9.3.5 Teva Pharmaceutical Acquires Ivax591
9.4 Licensing Agreement 601
9.4.1 Deals by Year of Consolidations601
9.4.2 Deals by Geography611
9.4.3 Deals by Deal value 621
9.5 Summary of Major M&A Deals621
9.5.1 AstraZeneca Enters Into Collaboration and Licensing Agreement with Targacept621
9.5.2 AstraZeneca Enters into Licensing Agreement with Rigel Pharmaceuticals631
9.5.3 Isis Pharmaceuticals Enters Into Licensing Agreement with Genzyme631
9.5.4 Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca631
9.5.5 Abraxis Enters Into License Agreement With ProMetic Life Sciences641
10 Nanotechnology in Drug Delivery Future Players659
Overview651
10.2 Abraxis Bioscience (Abraxis)661
10.2.1 Overview661
10.2.2 Business Description661
10.2.3 Product Portfolio671
10.3 AlphaRx Corporation 681
10.3.1 Overview681
10.3.2 Business Description681
10.3.3 Product Portfolio691
10.4 Camurus AB691
10.4.1 Overview691
10.4.2 Product Portfolio 701
10.5 Eurand 701
10.5.1 Overview701
10.5.2 Business Description701
10.5.3 Product Portfolio711
10.6 NanoBio Corporation 711
10.6.1 Overview711
10.6.2 Product Portfolio721
10.7 NanoCarrier 721
10.7.1 Overview721
10.7.2 Product Portfolio731
11 Nanaotechnology in Drug Delivery Appendix744
11.1 Market Definitions741
11.2 Abbreviations741
11.3 Research Methodology753
11.3.1 Coverage 761
11.3.2 Secondary Research761
11.3.3 Primary Research761
11.3.4 Expert Panel Validation771
11.4 Contact Us771
11.5 Disclaimer771
11.6 Sources771

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential" Dec 22, 2010. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Nanotechnology-in-Drug-Delivery-Technological-Improvements-and-Novel-Approaches-to-Fulfill-High-Potential-2115-122>
  
APA:
GBI Research Reports. (2010). Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential Dec 22, 2010. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Nanotechnology-in-Drug-Delivery-Technological-Improvements-and-Novel-Approaches-to-Fulfill-High-Potential-2115-122>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.